Brain imaging to predict toxicity in elderly patients after radiotherapy

Not Applicable

Completed

• Conditions: Glioblastoma; Cancer

• Registration Number: ISRCTN83254164
• Lead Sponsor: niversity Hospitals Sussex NHS Foundation Trust

Brief Summary

Poster results see attached file ISRCTN83254164_Poster.pdf Abstract submitted to European Association of Neuro-Oncology April 2023 (added 19/01/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-12-31
• Study Start: 2023-05-31
• Last Update Posted: 18 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Patients aged >65 years with a new diagnosis of GBM. Diagnosis made via histological confirmation following biopsy or debulking surgery or radiologically during an MDM meeting confirmed by a consultant neuroradiologist. This lower age limit is due to previous clinical trials which have established gold-standard treatment regimes for patients under the age of 65 years. Patients aged 65 years or over have less clinical trial data available to them and treatment decisions are more nuanced with a greater emphasis on quality of life given the poorer prognosis of older patients.
2. Patients undergoing radiotherapy treatment to the brain for the treatment of their GBM
3. Patients able to undergo an MRI scan
4. Patients undergoing treatment at one of the study centres
5. Patients have the capacity to participate in the study
6. Patients with physical impairments that prevent them from filling in their questionnaires involved in the study may still participate if they are able to communicate their answers through a third party

Exclusion Criteria

1. Patients not fit for radiotherapy treatment or having single-agent chemotherapy with no radiotherapy
2. Patients lacking capacity
3. Patients who do not have a sufficient grasp of the English language to be able to complete the questionnaires
4. Patients unable to communicate their responses to the questionnaires
5. Patients who are concurrently enrolled in a Clinical Trial of an Investigational Medicinal Product (CTIMP)

Study & Design

• Study Type: Observational
• Study Design: Not specified